Medicare coverage of buprenorphine-naloxone film surrounding generic entry
CONCLUSIONS: Medicare Part D plan formularies replaced brand-name buprenorphine-naloxone films with the newly approved generic versions. This was accompanied by a substantial decrease in estimated OOP cost faced by Part D enrollees. These changes could potentially increase access to buprenorphine among Medicare enrollees with opioid use disorder.PMID:37616154 | DOI:10.37765/ajmc.2023.89413 (Source: The American Journal of Managed Care)
Source: The American Journal of Managed Care - August 24, 2023 Category: Health Management Authors: Hao Zhang Yuhua Bao Shashi N Kapadia Source Type: research
Medicare coverage of buprenorphine-naloxone film surrounding generic entry
CONCLUSIONS: Medicare Part D plan formularies replaced brand-name buprenorphine-naloxone films with the newly approved generic versions. This was accompanied by a substantial decrease in estimated OOP cost faced by Part D enrollees. These changes could potentially increase access to buprenorphine among Medicare enrollees with opioid use disorder.PMID:37616154 | DOI:10.37765/ajmc.2023.89413 (Source: The American Journal of Managed Care)
Source: The American Journal of Managed Care - August 24, 2023 Category: Health Management Authors: Hao Zhang Yuhua Bao Shashi N Kapadia Source Type: research
Medicare coverage of buprenorphine-naloxone film surrounding generic entry
CONCLUSIONS: Medicare Part D plan formularies replaced brand-name buprenorphine-naloxone films with the newly approved generic versions. This was accompanied by a substantial decrease in estimated OOP cost faced by Part D enrollees. These changes could potentially increase access to buprenorphine among Medicare enrollees with opioid use disorder.PMID:37616154 | DOI:10.37765/ajmc.2023.89413 (Source: The American Journal of Managed Care)
Source: The American Journal of Managed Care - August 24, 2023 Category: Health Management Authors: Hao Zhang Yuhua Bao Shashi N Kapadia Source Type: research
Medicare coverage of buprenorphine-naloxone film surrounding generic entry
CONCLUSIONS: Medicare Part D plan formularies replaced brand-name buprenorphine-naloxone films with the newly approved generic versions. This was accompanied by a substantial decrease in estimated OOP cost faced by Part D enrollees. These changes could potentially increase access to buprenorphine among Medicare enrollees with opioid use disorder.PMID:37616154 | DOI:10.37765/ajmc.2023.89413 (Source: The American Journal of Managed Care)
Source: The American Journal of Managed Care - August 24, 2023 Category: Health Management Authors: Hao Zhang Yuhua Bao Shashi N Kapadia Source Type: research
Medicare coverage of buprenorphine-naloxone film surrounding generic entry
CONCLUSIONS: Medicare Part D plan formularies replaced brand-name buprenorphine-naloxone films with the newly approved generic versions. This was accompanied by a substantial decrease in estimated OOP cost faced by Part D enrollees. These changes could potentially increase access to buprenorphine among Medicare enrollees with opioid use disorder.PMID:37616154 | DOI:10.37765/ajmc.2023.89413 (Source: The American Journal of Managed Care)
Source: The American Journal of Managed Care - August 24, 2023 Category: Health Management Authors: Hao Zhang Yuhua Bao Shashi N Kapadia Source Type: research
Medicare coverage of buprenorphine-naloxone film surrounding generic entry
CONCLUSIONS: Medicare Part D plan formularies replaced brand-name buprenorphine-naloxone films with the newly approved generic versions. This was accompanied by a substantial decrease in estimated OOP cost faced by Part D enrollees. These changes could potentially increase access to buprenorphine among Medicare enrollees with opioid use disorder.PMID:37616154 | DOI:10.37765/ajmc.2023.89413 (Source: The American Journal of Managed Care)
Source: The American Journal of Managed Care - August 24, 2023 Category: Health Management Authors: Hao Zhang Yuhua Bao Shashi N Kapadia Source Type: research
Medicare coverage of buprenorphine-naloxone film surrounding generic entry
CONCLUSIONS: Medicare Part D plan formularies replaced brand-name buprenorphine-naloxone films with the newly approved generic versions. This was accompanied by a substantial decrease in estimated OOP cost faced by Part D enrollees. These changes could potentially increase access to buprenorphine among Medicare enrollees with opioid use disorder.PMID:37616154 | DOI:10.37765/ajmc.2023.89413 (Source: The American Journal of Managed Care)
Source: The American Journal of Managed Care - August 24, 2023 Category: Health Management Authors: Hao Zhang Yuhua Bao Shashi N Kapadia Source Type: research
Medicare coverage of buprenorphine-naloxone film surrounding generic entry
CONCLUSIONS: Medicare Part D plan formularies replaced brand-name buprenorphine-naloxone films with the newly approved generic versions. This was accompanied by a substantial decrease in estimated OOP cost faced by Part D enrollees. These changes could potentially increase access to buprenorphine among Medicare enrollees with opioid use disorder.PMID:37616154 | DOI:10.37765/ajmc.2023.89413 (Source: The American Journal of Managed Care)
Source: The American Journal of Managed Care - August 24, 2023 Category: Health Management Authors: Hao Zhang Yuhua Bao Shashi N Kapadia Source Type: research
Clinical and psychosocial outcomes by sex among individuals prescribed buprenorphine-naloxone (BUP-NX) or extended-release naltrexone (XR-NTX) for opioid use disorder
CONCLUSIONS: Further research should explore how to integrate employment support into OUD treatment to improve patient outcomes, particularly among women.SCIENTIFIC SIGNIFICANCE: The current study addressed gaps in the literature by examining sex differences in MOUD initiation and diverse treatment outcomes in a large, national sample.PMID:37583120 | DOI:10.1111/ajad.13463 (Source: American Journal on Addictions)
Source: American Journal on Addictions - August 16, 2023 Category: Addiction Authors: Margaret Paschen-Wolff Shelly Greenfield R Kathryn McHugh Kathleen Burlew Martina Pavlicova Tse-Hwei Choo Celestina Barbosa-Leiker Lesia M Ruglass Sarah Mennenga John Rotrosen Edward V Nunes Aimee N C Campbell Source Type: research
Clinical and psychosocial outcomes by sex among individuals prescribed buprenorphine-naloxone (BUP-NX) or extended-release naltrexone (XR-NTX) for opioid use disorder
CONCLUSIONS: Further research should explore how to integrate employment support into OUD treatment to improve patient outcomes, particularly among women.SCIENTIFIC SIGNIFICANCE: The current study addressed gaps in the literature by examining sex differences in MOUD initiation and diverse treatment outcomes in a large, national sample.PMID:37583120 | DOI:10.1111/ajad.13463 (Source: The American Journal on Addictions)
Source: The American Journal on Addictions - August 16, 2023 Category: Addiction Authors: Margaret Paschen-Wolff Shelly Greenfield R Kathryn McHugh Kathleen Burlew Martina Pavlicova Tse-Hwei Choo Celestina Barbosa-Leiker Lesia M Ruglass Sarah Mennenga John Rotrosen Edward V Nunes Aimee N C Campbell Source Type: research
Clinical and psychosocial outcomes by sex among individuals prescribed buprenorphine-naloxone (BUP-NX) or extended-release naltrexone (XR-NTX) for opioid use disorder
CONCLUSIONS: Further research should explore how to integrate employment support into OUD treatment to improve patient outcomes, particularly among women.SCIENTIFIC SIGNIFICANCE: The current study addressed gaps in the literature by examining sex differences in MOUD initiation and diverse treatment outcomes in a large, national sample.PMID:37583120 | DOI:10.1111/ajad.13463 (Source: American Journal on Addictions)
Source: American Journal on Addictions - August 16, 2023 Category: Addiction Authors: Margaret Paschen-Wolff Shelly Greenfield R Kathryn McHugh Kathleen Burlew Martina Pavlicova Tse-Hwei Choo Celestina Barbosa-Leiker Lesia M Ruglass Sarah Mennenga John Rotrosen Edward V Nunes Aimee N C Campbell Source Type: research
Clinical and psychosocial outcomes by sex among individuals prescribed buprenorphine-naloxone (BUP-NX) or extended-release naltrexone (XR-NTX) for opioid use disorder
CONCLUSIONS: Further research should explore how to integrate employment support into OUD treatment to improve patient outcomes, particularly among women.SCIENTIFIC SIGNIFICANCE: The current study addressed gaps in the literature by examining sex differences in MOUD initiation and diverse treatment outcomes in a large, national sample.PMID:37583120 | DOI:10.1111/ajad.13463 (Source: The American Journal on Addictions)
Source: The American Journal on Addictions - August 16, 2023 Category: Addiction Authors: Margaret Paschen-Wolff Shelly Greenfield R Kathryn McHugh Kathleen Burlew Martina Pavlicova Tse-Hwei Choo Celestina Barbosa-Leiker Lesia M Ruglass Sarah Mennenga John Rotrosen Edward V Nunes Aimee N C Campbell Source Type: research
Clinical and psychosocial outcomes by sex among individuals prescribed buprenorphine-naloxone (BUP-NX) or extended-release naltrexone (XR-NTX) for opioid use disorder
CONCLUSIONS: Further research should explore how to integrate employment support into OUD treatment to improve patient outcomes, particularly among women.SCIENTIFIC SIGNIFICANCE: The current study addressed gaps in the literature by examining sex differences in MOUD initiation and diverse treatment outcomes in a large, national sample.PMID:37583120 | DOI:10.1111/ajad.13463 (Source: American Journal on Addictions)
Source: American Journal on Addictions - August 16, 2023 Category: Addiction Authors: Margaret Paschen-Wolff Shelly F Greenfield R Kathryn McHugh Kathleen Burlew Martina Pavlicova Tse-Hwei Choo Celestina Barbosa-Leiker Lesia M Ruglass Sarah Mennenga John Rotrosen Edward V Nunes Aimee N C Campbell Source Type: research
Clinical and psychosocial outcomes by sex among individuals prescribed buprenorphine-naloxone (BUP-NX) or extended-release naltrexone (XR-NTX) for opioid use disorder
CONCLUSIONS: Further research should explore how to integrate employment support into OUD treatment to improve patient outcomes, particularly among women.SCIENTIFIC SIGNIFICANCE: The current study addressed gaps in the literature by examining sex differences in MOUD initiation and diverse treatment outcomes in a large, national sample.PMID:37583120 | DOI:10.1111/ajad.13463 (Source: The American Journal on Addictions)
Source: The American Journal on Addictions - August 16, 2023 Category: Addiction Authors: Margaret Paschen-Wolff Shelly F Greenfield R Kathryn McHugh Kathleen Burlew Martina Pavlicova Tse-Hwei Choo Celestina Barbosa-Leiker Lesia M Ruglass Sarah Mennenga John Rotrosen Edward V Nunes Aimee N C Campbell Source Type: research
Clinical and psychosocial outcomes by sex among individuals prescribed buprenorphine-naloxone (BUP-NX) or extended-release naltrexone (XR-NTX) for opioid use disorder
CONCLUSIONS: Further research should explore how to integrate employment support into OUD treatment to improve patient outcomes, particularly among women.SCIENTIFIC SIGNIFICANCE: The current study addressed gaps in the literature by examining sex differences in MOUD initiation and diverse treatment outcomes in a large, national sample.PMID:37583120 | DOI:10.1111/ajad.13463 (Source: American Journal on Addictions)
Source: American Journal on Addictions - August 16, 2023 Category: Addiction Authors: Margaret Paschen-Wolff Shelly F Greenfield R Kathryn McHugh Kathleen Burlew Martina Pavlicova Tse-Hwei Choo Celestina Barbosa-Leiker Lesia M Ruglass Sarah Mennenga John Rotrosen Edward V Nunes Aimee N C Campbell Source Type: research
